Showing results (301-310 of 586) with videos related to
Sort By:
Pageof 59
Antimicrobial Agents and Chemotherapy|February 1, 1987
In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycinA L Barry, C Thornsberry, R N JonesJournal of Clinical Microbiology|January 1, 1986
Evaluation of teicoplanin and vancomycin disk susceptibility testsA L Barry, C Thornsberry, R N JonesAntimicrobial Agents and Chemotherapy|April 1, 1989
Antibacterial activity of trospectomycin (U-63366F) and initial evaluations of disk diffusion susceptibility testsA L Barry, R N Jones, C ThornsberryJournal of Clinical Microbiology|August 1, 1983
Proposed zone standards for interpretation of fortimicin A disk diffusion testsA L Barry, C Thornsberry, R N JonesJournal of Clinical Microbiology|March 1, 1985
Feasibility study of disk diffusion susceptibility tests with Mueller-Hinton broth solidified with Gelrite, an agar substituteA L Barry, L Creitz, R R PackerThe Journal of Antimicrobial Chemotherapy|March 1, 1989
In-vitro activity of the penem, FCE 22101, and tentative interpretive criteria for disc susceptibility testsA L Barry, R N Jones, C ThornsberryJournal of Clinical Microbiology|July 1, 1983
Disk agar diffusion susceptibility testing with 30-micrograms ceftazidime disks: confirmation of interpretive breakpoints and quality control guidelinesR N Jones, A L Barry, C ThornsberryAntimicrobial Agents and Chemotherapy|January 1, 1986
In vitro evaluation of A-56619 and A-56620, two new quinolonesA L Barry, C Thornsberry, R N JonesAntimicrobial Agents and Chemotherapy|June 1, 1984
In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporinR N Jones, C Thornsberry, A L BarryJournal of Clinical Microbiology|February 1, 1983
Evaluation of the cefonicid disk test criteria, including disk quality control guidelinesA L Barry, R N Jones, C ThornsberryPageof 59